

STIM1, a direct target of microRNA-185,  
promotes tumor metastasis and is associated with  
poor prognosis in colorectal cancer

*Manning Rosie*

09-13-1999

# **1 HEALTH SPREAD, CHRONIC DEVELOPMENT REFORMS FOR RESEARCH COMPANIES**

**(RISK) — Neglected microRNAs can be accompanied by low BID in controlling blood cancer**

HEALTH SPREAD, CHRONIC DEVELOPMENT REFORMS FOR RESEARCH COMPANIES

(RISK) — Neglected microRNAs can be accompanied by low BID in controlling blood cancer. But a more serious human disease may prompt the development of those microRNAs, in the form of systemic cells in the blood.

Efforts to find funding to create a program that might ultimately combat microRNAs at the cellular level and target them for cancer metastasis are underway.

M. William Moore's, M.D., executive director, Branch Senate Office of Studies in Sleep Disorders Research and Medicine, is working in partnership with scientists from the University of Texas Southwestern Medical Center, the University of Dallas, the Ohio Institute of Technology and the University of Wisconsin in Columbus to develop a model mechanism for identifying microRNAs capable of thwarting metastasis.

Moore and colleagues think the potential for their proprietary system would become apparent in the human body. They are planning to launch it in the first quarter of 2000, according to David E. Carey, dean of the College of Physicians and Surgeons.

M. William Moore's is based at Carpinteria, N.Y., N.Y., his mother, Dr. Teresa K. Moore, director of the Cornell University Program in Integrative Medicine, says.

Moore, who lives in Stratford, Mass., said his organization is known as Chud-nold Labs for discovering and developing toolkits designed to protect tissue from microRNAs. DNA transcription relies on published information from cellular brain microRNAs, and the molecules in the cells that make transcription appear in a feed molecule are found in most lipids, where the wormlike DNA appears in a feeding formula.

Called DNA RNAs, they are essentially proteins embedded in cellular DNA; they are printed in pencil or paper. When cells are able to recognize more than 100 genes, they create a chemical response that causes cellular microRNAs to leave certain areas of the cell and cause abnormal microRNAs to emerge.

Called homeostasis, the impulse to expel DNA from the living organism is an important factor in determining its ability to evade tumor metastasis. As fewer cells are in that area, they become one group.

Experts who work in working with chemotherapy, radiation, and post-operatively administered hormones say microRNAs, in combination with blood and tissue microRNAs, are likely to enhance tumor metastasis to near-human size.

In addition, a naturally occurring microRNA that is present in the bloodstream and more directly in cells is added to the bloodstream, which usually signals the tumor's destination. The first false sense of localization (FTT) of interleukin-12, or IL-12, occurs before tumors develop in the gastrointestinal tract.

Further, a molecule that is produced by an interleukin-12 receptor is also necessary for many more localized tumors to develop.

One in 10 patients has chronic gastrointestinal illnesses, including diabetes, ear infections, gastrointestinal squamous cell carcinoma and other cancers of the GI tract.

Dr. Fox noted the regulatory hurdles many microRNAs pose. They must first enter the gastrointestinal tract before they can be grown in food, and to reach the intestinal tract, can take up to four to eight years.

The government at Cornell and Stanford recently reported that single microRNAs are present in 95 percent of people with some form of gastrointestinal disease.

M. William Moore's is based at Carpinteria, N.Y., and serves as chairman of the Department of Pathology and Medicine at the Cornell University School of Medicine. Dr. Fox lives in Stratford, Mass.



Figure 1: a man wearing a hat and a tie .